VC23 is an investment management company specializing in early-stage biotechnology and technology ventures. The firm leads capital rounds and co-invests with other VC firms, focusing on companies with breakthrough technologies. VC23 typically participates in Series A rounds, with investments ranging from $5 million to $10 million based on their portfolio companies' funding.
Notable portfolio companies include Codetta, Fluent BioSciences, and Tangen Biosciences. VC23 recognizes the transformative potential of biotechnology, drawing parallels to historical innovations like the printing press and microprocessors. The firm values versatility and collaboration, seeking to partner with management teams and co-investors to drive innovation in the rapidly evolving biotech landscape.
Portfolio Snapshot
Observed round participation, including acquisitions and grants. Current holdings, investor exits, and write-offs are not established.